Compulsory licensing under TRIPS means that India can allow manufacturing without running afoul of international trade law, though if enough non-Indians started doing this it could cause some headaches due to the &quot;predominantly for domestic use&quot; clause. But in reality there&#x27;s no way that pharma companies can stop developing countries from manufacturing critical medicines.